Back to catalogue
№ 295 15 filings · 2025-10-01 → 2026-09-04

MEDPAL AI PLC

MPAL
Health Care Share price 5.23p Market cap £46m Overall fit 175 /1000

Genuine execution and revenue ramp but fails the investor's three tests: it is an AI-marketing spender not an AI receiver, valuation already discounts the operational bull case, and the balance sheet is fragile with a going-concern-flagged audit and chronic dilution.

Fair value range 3p–6p Mid case · £33m
Absolute upside -28.8% vs current market cap
Conviction 3/5 confidence in overvalued call
Supports the call
  • Frequent, granular operational KPI disclosure (monthly items, ARR, GM)
  • Multiple valuation approaches (EV/Sales, SaaS multiple, dilution-adjusted) converge on similar range
  • Clear management-stated breakeven threshold (80k items/month) provides an anchor
Limits the call
  • Only one audited year as a listed company, and that period was pre-revenue
  • Further equity dilution near-certain, timing and quantum will move per-share fair value
Methodology

Hybrid forward EV/Sales with SaaS uplift and dilution haircut

In one line · bull case

Fast-executing pharmacy and care-home-SaaS rollup with genuine three-engine revenue ramp and real operating-leverage headroom in idle robotic capacity.

In one line · biggest risk

The business is structurally reliant on continuous equity dilution to reach breakeven, and per-share value is likely to be eroded even if the operational plan is delivered.

Drivers
AI beneficiary 20 /100
Uses Anthropic Claude and Google Vertex AI as infrastructure; is a pharmacy rollup with AI marketing overlay, not an AI receiver.
Operating leverage 55 /100
Fixed-cost robotic dispensing hubs give real leverage; ~34% pharmacy GM caps the incremental drop-through, eMARx SaaS at 82% GM is the true leverage engine but tiny.
Earnings vs expectations 50 /100
Not enough data — one FY report as listed company, no explicit prior guidance to score against; trading updates trend positive.
Growth momentum 80 /100
£0 to £8.6m ARR in nine months across three revenue streams; monthly item counts compounding.
Moat 25 /100
NHS DSP licence has some scarcity (GPhC stopped issuing June 2025) but is not exclusive; eMARx competes with several UK vendors.
Earnings quality 25 /100
Loss-making, heavy share-based comp, related-party dealings, working-capital stress — cash was £4,189 at H1 balance sheet date.
Management quality 30 /100
Founder executes at speed but concerning pattern: related-party Runcorn deal, serial dilution at falling prices, promotional tone, Chairman departure, AGM auditor error.
Cyclicality 15 /100
NHS prescriptions and care-home dispensing highly defensive; GLP-1 demand is secular.
Leverage 30 /100
Modest reported borrowings but structural cash fragility; auditor flagged material uncertainty on going concern.
Value-trap signals · 7
  • Going-concern material-uncertainty audit opinion for FY25
  • Cash of £4,189 at H1 FY26 balance-sheet date
  • Serial dilution: share count from ~46m to 779m in twelve months at declining placing prices
  • Related-party pattern around Runcorn acquisition and CEO IP contribution
  • Repeated settlement of adviser fees in shares signalling cash pressure
  • Highly promotional CEO commentary style
  • Rapid strategic pivot from AI wellness app to pharmacy rollup within 6 months of IPO

MEDPAL AI PLC (MPAL) — Investment Research Note

Executive summary

MedPal AI is an AIM-listed UK healthcare rollup that, in the twelve months since its August 2025 IPO as a pre-revenue "AI wellness app," has bolted together an NHS distance-selling pharmacy (via administration-sale acquisitions of Universal and Remedi), a GLP-1 weight-loss clinic (New Health / MedPal.clinic), a care-home eMAR SaaS asset (eMARx) and a Claude-based agentic-AI companion (Juno). Operating trajectory: from £nil revenue at IPO to c.£8.6m annualised recurring revenue by July 2026 2026-08-04 trading update, but on an H1-26 pre-tax loss of £3.27m 2026-05-29 interims and £4,189 of cash at the balance sheet date, sustained by a near-continuous series of dilutive placings (share count rose from ~46m to 779m in twelve months). The single most important valuation question is whether the pharmacy platform reaches its stated 80,000-items/month EBITDA-breakeven threshold 2026-04-29 before further equity dilution erodes the per-share value — currently the run-rate is ~47,000 items/month 2026-08-04.

Fair value estimate

  • Fair value range: 3.0p – 5.5p per share (implied market cap £23m – £43m on the current 779m-share count)
  • Midpoint: 4.2p per share (£33m market cap)
  • Methodology: hybrid forward EV/Sales on plausible ~FY27 run-rate revenue, with a SaaS uplift for eMARx and haircut for further dilution.
    • Pharmacy: ~£10-12m revenue at 80k items/month × ~34% GM → 1.0-1.5x sales = £10-18m
    • New Health private GLP-1: ~£4-6m ARR by year-end, but competitive vs. Voy/Juniper/MedExpress — 1.0-1.5x = £4-9m
    • eMARx SaaS: £0.85m ARR at 82% GM, ~£0.1m PAT — modest SaaS multiple 6-10x sales = £5-8m
    • Juno / Health OS optionality: £2-5m
    • Aggregate: £21m – £40m enterprise value. Add ~£5m residual cash from July 2026 raise, subtract capex/burn = £22-43m equity value pre-dilution.
    • Applied a further ~10% dilution allowance for near-certain additional issuance given the burn.
  • Absolute versus current £40.5m market cap: -19% to +6%, midpoint approximately -18%.
  • View: fair to modestly overvalued — the market is already crediting most of the near-term revenue ramp.

Sector context

  • Sector confirmed: Health Care (ICB). MedPal sits in the digital-health / online pharmacy sub-sector.
  • Quality/growth/leverage profile is below typical peers: sub-scale, loss-making, chronic dilution, going-concern-flagged audit opinion 2026-02-27 final results, versus profitable listed peers.
  • Listed comparables: PHOENIX Group and Cambridge Cognition (partial), and privately: Pharmacy2U, Well Pharmacy, Numan, Voy. In GLP-1 clinics the closest listed analogues are the US telehealth names (Hims & Hers) but at wildly different scale and margin.

Investment thesis (3 bullets)

  1. Ferocious revenue ramp from a standing start: £0 to £8.6m annualised in nine months across three complementary channels (NHS prescriptions £5.5m ARR, private GLP-1 £2.2m ARR, SaaS £0.85m ARR) — all disclosed as repeat/recurring 2026-08-04 trading update. Small absolute base but the trajectory demonstrates execution capability.
  2. Robotic dispensing platform with genuine operating leverage headroom: two BD Rowa/Omnicell-equipped hubs (Swaffham + Runcorn) with combined capacity comfortably above the stated 80,000-item/month breakeven. Runcorn alone dispensed >100k items/month at its 2024 peak under prior ownership 2026-04-29 Remedi acquisition. Reactivating idle capacity is materially higher-margin than greenfield build-out.
  3. eMARx is a real, profitable SaaS asset acquired cheaply: £446k total consideration for a business with £0.74m revenue (+19% YoY, tripled over three years), £0.11m PAT and ~82% gross margins 2026-07-20 eMARx acquisition. Provides a genuine software gross-margin layer within an otherwise pharmacy-margin group, and a differentiated cross-sell hook into the c.16,500 UK care-home addressable market.

Key risks (3 bullets)

  1. Chronic dilution / going-concern posture: share count expanded from ~46m to 779m in twelve months; cash was £4,189 at 28 Feb 2026 2026-05-29 interims; auditor flagged a material uncertainty on going concern 2026-02-27. Even after the July 2026 £5m raise at 3.5p, the FY27 burn trajectory suggests further issuance is likely.
  2. GLP-1 competitive intensity and CAC exposure: New Health explicitly plans to spend c.£1.3m on marketing to compete with MedExpress, Voy, Juniper, Hims 2026-04-17 placing. These are well-funded competitors with mature acquisition funnels; MedPal is claiming a defensible edge from vertical integration but has no disclosed CAC/LTV metrics to substantiate this.
  3. Governance and related-party pattern: the Runcorn asset was originally acquired in the CEO's personal name and later novated to the company 2026-05-29 note 9 / 2026-04-29 announcement, intercompany reimbursement of £280k of CEO-incurred costs, heavy insider option/warrant issuance (52m+ instruments to directors and connected parties at low strikes), Chairman departure four months post-IPO 2026-03-09, and an initial AGM announcement naming the wrong auditor 2026-04-02 replacement. Individually manageable, collectively concerning for a business dependent on continual equity funding.

Operating leverage

The business has a legitimate operating-leverage story but it has not yet crystallised. Fixed-cost anchors are the two robotic dispensing hubs (BD Rowa/Omnicell), central regulatory/clinical staffing and the technology stack — versus variable costs dominated by drug COGS at ~66% of revenue (implied by 34% NHS pharmacy gross margin 2026-05-29). Management guides pharmacy-level EBITDA breakeven at 80,000 items/month; the group ran 47,223 items in July 2026 2026-08-04, so approximately 70% incremental volume growth is required before the pharmacy vertical stops absorbing cash. Because the drug-cost line dominates NHS-pharmacy economics, incremental margin above breakeven is modest — the operating-leverage kicker is real but bounded (a 10-20% revenue beat probably adds meaningful, not multiple, operating profit at the pharmacy). The genuinely operationally-levered assets are (a) eMARx SaaS at 82% GM — where every incremental subscription drops almost entirely to gross profit — and (b) New Health, whose LTV appears high (£2,400 annual recurring per patient per management 2026-07-03 placing) but whose CAC is unquantified. Absent CAC disclosure, the contribution-margin picture is unverifiable. Net: modest operating leverage today, potentially significant if eMARx and New Health scale as intended, but downside is that the pharmacy stays sub-scale and cash keeps burning.

Value-trap signals

  • Chronic serial dilution at ever-lower prices between Aug 2025 and April 2026 (IPO 4.0p → 8.0p → 6.6p → 6.1p → 5.2p → 2.5p), then modest recovery.
  • Going-concern material-uncertainty audit opinion 2026-02-27.
  • Cash of £4,189 at H1 balance-sheet date 2026-05-29.
  • Heavy related-party dealings around the Runcorn acquisition and IP contribution.
  • Fee-share issuance pattern (repeatedly settling advisers with paper) — signals cash pressure.
  • Extremely promotional CEO commentary ("in the air, travelling at speed, and climbing"; "no longer taxiing to the runway").
  • Very rapid pivot: IPO'd as an AI wellness app; twelve months later is essentially a pharmacy rollup with AI branding.

Earnings vs. expectations

The company only has one full audited year (FY25, to 31 Aug 2025) as an AIM-listed entity — pre-revenue at IPO and a £4.0m pre-tax loss versus an implicit "planned investment cycle" 2026-02-27. Trading updates have consistently beaten or upgraded on volume run-rate — 28,789 items (Nov 2025) → 33,433 (Dec 2025) → 41,000+ (Mar 2026) → 42,250 (May 2026) → 47,223 (Jul 2026) 2025-12-04, 2026-01-05, 2026-04-29, 2026-08-04. There is no analyst consensus visible in the filings and no explicit prior guidance to check hit rates against. Pattern: management sets qualitative/aspirational milestones ("pathway to 80k items/month breakeven"), then reports monthly volume progress; whether the 80k threshold is hit on the current timetable, and whether pharmacy-level breakeven translates to group breakeven (which requires clinic and central overhead absorption), remains unproven.

Conviction

3 — moderate. Supports: (a) filings are frequent, granular and well-disclosed on operational KPIs (monthly items, ARR, GM), (b) the valuation framework using EV/Sales on plausible run-rate revenue is defensible, (c) triangulation across pharmacy-multiple, SaaS-multiple and dilution-adjusted per-share arithmetic converges on a similar range. Limits: (a) audit-level financials are only through Aug 2025 (pre-revenue period), so the true unit economics of the pharmacy at scale are unverified; (b) further dilution is near-certain and its timing/quantum will materially affect per-share fair value.

Driver scoring rationale (0-100)

  • ai_beneficiary (20): MedPal spends on AI (Anthropic Claude for Juno, Google Vertex AI for triage) rather than receiving AI dollars. "AI-native" branding is marketing overlay on a pharmacy rollup.
  • operating_leverage (55): Fixed-cost robotic hubs with spare capacity give real leverage — but pharmacy GM (~34%) caps the incremental margin. eMARx SaaS at 82% GM lifts the group-average but at tiny scale.
  • earnings_surprise_trend (50): Insufficient history — one FY report as a listed company and no explicit prior guidance to score against. Trading updates trend positive.
  • cyclicality (15): NHS prescriptions and care-home dispensing are highly defensive; GLP-1 demand is secular. Very low cyclicality.
  • moat (25): NHS DSP licence has some scarcity value (GPhC stopped issuing them in June 2025 2026-02-27) but is not exclusive; robotic dispensing is not proprietary; eMARx is niche but competes with several UK eMAR vendors.
  • leverage (30): Modest reported borrowings but structural fragility — burns cash, dependent on serial equity funding. Not classic debt leverage but distress-adjacent.
  • earnings_quality (25): Loss-making, heavy share-based compensation (£3.4m in FY25 audit), related-party dealings, working-capital stress; H1 FY26 delivered £1.6m revenue but only £4,189 cash at period end.
  • management_quality (30): Founder executes at speed and has assembled the assets cheaply, but concerning signals: related-party pattern, chronic dilution at declining prices, promotional tone, Chairman departure, initial AGM announcement mis-stating the auditor.
  • growth_momentum (80): From zero to £8.6m ARR in nine months is genuinely rapid; monthly item counts are compounding.

Overall score rationale

This is an interesting operational story wrapped in AI marketing that does not fit the "AI receiver" thesis. It has some operating leverage but limited by pharmacy gross margins, is trading at a full valuation on run-rate revenue, and has weak downside protection given cash burn, going-concern language, and near-certain further dilution. It is not a candidate for a portfolio built around AI-receiver + valuation discipline + operating-leverage-with-quality-balance-sheet criteria.

Filings consulted · 17

Every document the LLM read for this note. Click any row to open the source.

  1. 2026-09-04Completion OF Emarx Acquisition Issue OF Equity2026-09-04_9756694_completion-of-emarx-acquisition-issue-of-equity.md0.75
  2. 2026-08-04July Trading Update2026-08-04_9702437_july-trading-update.md0.85
  3. 2026-07-20Acquisition OF Emarx2026-07-20_9675774_acquisition-of-emarx.md0.75
  4. 2026-07-03Placing TO Raise 5M2026-07-03_9650670_placing-to-raise-5m.md0.70
  5. 2026-05-29Half Year Financial Report2026-05-29_9590889_half-year-financial-report.md0.90
  6. 2026-04-29Acquisition OF Remedi Pharmacy Assets2026-04-29_9542858_acquisition-of-remedi-pharmacy-assets.md0.75
  7. 2026-04-17Placing TO Raise 3M2026-04-17_9524817_placing-to-raise-3m.md0.70
  8. 2026-04-02Result OF Agm Replacement2026-04-02_9505796_result-of-agm-replacement.md0.30
  9. 2026-03-30Result OF Agm2026-03-30_9498322_result-of-agm.md0.30
  10. 2026-03-20Placing And Wrap Retail Offer2026-03-20_9485280_placing-and-wrap-retail-offer.md0.70
  11. 2026-03-09Notice OF Agm And Board Changes2026-03-09_9464392_notice-of-agm-and-board-changes.md0.30
  12. 2026-02-27Final Results2026-02-27_9451802_final-results.md0.85
  13. 2026-02-16Completion OF Acquisition2026-02-16_9431342_completion-of-acquisition.md0.64
  14. 2026-01-05Trading Update2026-01-05_9333694_trading-update.md0.72
  15. 2025-12-04Trading Update And AT The Market Facility2025-12-04_9274561_trading-update-and-at-the-market-facility.md0.72
  16. 2025-10-01Placing TO Raise 400 0002025-10-01_9144588_placing-to-raise-400-000.md0.59
  17. 2025-10-01Acquisition OF Assets From Universal Pharmacy Ltd2025-10-01_9144543_acquisition-of-assets-from-universal-pharmacy-ltd.md0.64

This research note was authored by a large language model after reading 15 regulatory filings published between 2025-10-01 and 2026-09-04. Each citation refers to a specific RNS announcement in the underlying data set. The note is an opinion, not advice. Do your own work before risking capital.